Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RISANKIZUMAB-RZAA Cause Prostatic specific antigen increased? 37 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Prostatic specific antigen increased have been filed in association with RISANKIZUMAB-RZAA. This represents 0.1% of all adverse event reports for RISANKIZUMAB-RZAA.

37
Reports of Prostatic specific antigen increased with RISANKIZUMAB-RZAA
0.1%
of all RISANKIZUMAB-RZAA reports
0
Deaths
5
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From RISANKIZUMAB-RZAA?

Of the 37 reports, 5 (13.5%) required hospitalization.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does RISANKIZUMAB-RZAA Cause?

Psoriasis (6,896) Drug ineffective (2,885) Pain (2,584) Fatigue (2,483) Arthralgia (2,419) Pruritus (2,311) Covid-19 (2,145) Death (1,700) Fall (1,666) Surgery (1,662)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which RISANKIZUMAB-RZAA Alternatives Have Lower Prostatic specific antigen increased Risk?

RISANKIZUMAB-RZAA vs RISDIPLAM RISANKIZUMAB-RZAA vs RISEDRONATE RISANKIZUMAB-RZAA vs RISEDRONIC ACID RISANKIZUMAB-RZAA vs RISPERDAL RISANKIZUMAB-RZAA vs RISPERDAL CONSTA

Related Pages

RISANKIZUMAB-RZAA Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased RISANKIZUMAB-RZAA Demographics